University of Iowa Holden Comprehensive Cancer Center

Recent papers from University of Iowa Holden Comprehensive Cancer Center

1. Evaluating cancer survival among American Indian and Alaska Native patients living in Purchased/Referred Care Delivery Areas (PRCDA) and non-PRCDA countiesBMC Cancer · 2026
2. Case Report: Two cases of pediatric neurodevelopmental disorders associated with the DPYD c.1905+1G>A genetic variantFrontiers in Genetics · 2026
3. Parasitic infection shapes host metabolism, thermal tolerance and microbial diversityISME Host Microbe · 2026
4. Body mass index at diagnosis, postdiagnosis change, and role of metabolic comorbidities in relation to survival in nonmetastatic renal cell carcinoma patientsCancer · 2026
5. Timing of FDA-Defined Adequate BCG Therapy and Oncologic Outcomes in High-Risk Non-Muscle-Invasive Bladder CancerUrology Practice · 2026
6. Patient perspectives on gene therapies and gene editing for familial cardiomyopathiesBMC Medical Genomics · 2026
7. Contemporary Management and Rechallenge Practices for 5‐Fluorouracil–Associated Cardiotoxicity: Insights From an International Cardio‐Oncology Society SurveyJournal of the American Heart Association · 2026
8. Patient perspectives on gene therapies and gene editing for familial cardiomyopathiesBMC Medical Genomics · 2026
9. Care delivery among patients with early-onset versus average-onset cholangiocarcinoma: a nationwide retrospective analysisESMO Gastrointestinal Oncology · 2026
10. Combination of Immune Checkpoint Inhibitors With Vascular Endothelial Growth Factor–Targeted Agents in Advanced Gastric and Gastroesophageal AdenocarcinomaAmerican Journal of Clinical Oncology · 2026
11. Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinomaJournal for ImmunoTherapy of Cancer · 2026
12. Secreted nuclease effector neutralization by active site mimicry in BacillotamBio · 2026
13. Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trialNature Medicine · 2026
14. A Patient-Led Survey of Antibody Drug Conjugate Usage and Dosing for People Living With Metastatic Breast CancerJournal of Patient Experience · 2026
15. Characteristics and clinical outcomes of newly diagnosed acute myeloid leukemia with MAPK pathway mutations: A referral-center retrospective analysis.Journal of Clinical Oncology · 2026
16. Real-world validation of the 2025 IMWG high-risk criteria in multiple myeloma.Journal of Clinical Oncology · 2026
17. Reprogramming tumor-associated immune cells with Z-007, a first-in-class systemic TLR7/8/9 agonist.Journal of Clinical Oncology · 2026
18. A retrospective analysis of patients with metastatic melanoma treated with sequential metronomic temozolomide after immune therapy failure.Journal of Clinical Oncology · 2026
19. ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC).Journal of Clinical Oncology · 2026
20. Genomic predictors of response to cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): A real-world analysis from the PROMISE registry.Journal of Clinical Oncology · 2026